Evaluating cancer immunotherapy effectiveness in lung and esophageal cancer patients
Investigating the Biomarkers in Tumor Microenvironment and Peripheral Blood Microenvironment to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
This study is testing how well immunotherapy works for people with lung and esophageal cancer by looking at changes in their immune cells before and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Soochow University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Suzhou, Jiangsu) |
| Trial ID | NCT06790797 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the impact of immunotherapy on the immune status of patients with lung and esophageal cancer. Researchers will collect tumor tissue and peripheral blood samples before and after treatment to analyze changes in cancer-specific T-cell populations. Techniques such as single-cell RNA sequencing, multiplex immunohistochemistry, and flow cytometry will be employed to identify potential biomarkers that predict the efficacy of immunotherapy. The goal is to understand how these biomarkers correlate with treatment responses and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with a confirmed diagnosis of lung or esophageal cancer who are set to receive PD-1/PD-L1 antibody immunotherapy.
Not a fit: Patients with hematogenic infectious diseases, immediate treatment needs, or severe mental illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prediction of immunotherapy responses, allowing for more personalized treatment plans for cancer patients.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for immunotherapy efficacy, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive PD-1/PD-L1 antibody immunotherapy; * Age between 18 and 80 years old; * ECOG PS score of 0 or 1; * Adequate organ and bone marrow function; * Anticipated survival time of at least 12 weeks; * Willing and able to provide written informed consent. Exclusion Criteria: * Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C. * Patients with tumor emergencies that require immediate treatment. * Poor vascular conditions. * Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy. * Patients with hematogenic infectious diseases, such as HBV. * Patients with psychiatric disorders or severe mental illnesses. * Patients who have difficulty communicating or are unable to be followed up for a long time. * Other situations that are not suitable for inclusion in the study.
Where this trial is running
Suzhou, Jiangsu
- The first affiliated hospital of soochow university — Suzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Mi Liu
- Email: mi.liu831116@icoud.com
- Phone: 86-0512-67972216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.